Study study type PathologyT1T0Patientssample sizesROB Results

la/mBC - HR-positive - 1st line (L1) breast cancer - HR positive la/mBC - HR positive la/mBC - HR-positive - 1st line (L1)

versus fulvestrant
lapatinib plus fulvestrant
CALGB 40302, 2014
  NCT00390455
RCTla/mBC - HR-positive - 1st line (L1)lapatinib plus fulvestrantplacebo plus fulvestrantPostmenauposal women with stage III or IV HR-positive BC (Er and/or PR positive). Originally with HER2-positive, then an amendment to include tumors regardless of HER2 status. Patients had one or two prior endocrine treatments for at least 3 months without tumor progression in either the adjuvant or metastatic setting.-/-NA
suggested
  • inconclusive 4 % increase in progression or deaths (PFS) (PE)